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Abstract
Background: Prosthetic joint infection is an uncommon but serious complication of hip replacement. There are
two main surgical treatment options, with the choice largely based on the preference of the surgeon. Evidence is
required regarding the comparative effectiveness of one-stage and two-stage revision to prevent reinfection after
prosthetic joint infection.
Methods: We conducted a systematic review to identify randomised controlled trials, systematic reviews and
longitudinal studies in unselected patients with infection treated exclusively by one- or two-stage methods or by
any method. The Embase, MEDLINE and Cochrane databases were searched up to March 2011. Reference lists were
checked, and citations of key articles were identified by using the ISI Web of Science portal. Classification of studies
and data extraction were performed independently by two reviewers. The outcome measure studied was
reinfection within 2 years. Data were combined to produce pooled random-effects estimates using the Freeman-
Tukey arc-sine transformation.
Results: We identified 62 relevant studies comprising 4,197 patients. Regardless of treatment, the overall rate of
reinfection after any treatment was 10.1% (95% CI = 8.2 to 12.0). In 11 studies comprising 1,225 patients with
infected hip prostheses who underwent exclusively one-stage revision, the rate of reinfection was 8.6% (95% CI =
4.5 to 13.9). After two-stage revision exclusively in 28 studies comprising 1,188 patients, the rate of reinfection was
10.2% (95% CI = 7.7 to 12.9).
Conclusion: Evidence of the relative effectiveness of one- and two-stage revision in preventing reinfection of hip
prostheses is largely based on interpretation of longitudinal studies. There is no suggestion in the published
studies that one- or two stage methods have different reinfection outcomes. Randomised trials are needed to
establish optimum management strategies.
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Background
Hip replacement is widely used to treat pain associated
with diseased or damaged joints. During the one-year
period between April 2009 and March 2010, there were
71,021 primary hip replacement operations recorded in
the National Joint Registry for England and Wales [1].
In the United States in 2006, the estimated number of
hospital discharges after hip replacement was 231,000
[2], with demand predicted to increase substantially [3].
Deep prosthetic joint infection is an uncommon but
serious complication of hip replacement [4]. Estimated
incidences in UK populations are 0.45% to 0.57% [5,6],
and the estimated incidence is 0.88% in the United
States [7]. Infections that occur within 2 years of surgery
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any medium, provided the original work is properly cited.are usually surgically acquired [8]. Surgical site infec-
tions have a very negative effect on patients. Typically,
patients describe extreme pain, prolonged immobilisa-
tion, isolation and insecurity, as well as feelings of hope-
lessness [9]. Deep infection of hip prostheses puts
patients at risk for these problems, and, if untreated,
they can result in severe pain, persistent dislocation and
death [10].
Conservative treatment with prosthesis retention may
be considered in early infection if there is no evidence
of prosthesis loosening or significant damage to soft tis-
sue, as well as for infections that can be treated with
antibiotics [8]. Typical rates of hip infection clearance of
89% [11] and 87% [12] have been reported recently.
However, the need for long-term and possibly lifelong
antibiotic treatment is acknowledged [12]. Treatment
with prosthesis retention is not recorded in the National
Joint Registry for England and Wales, but typically
about 19% of prosthetic hip infections may be treated
by using this method [13].
For the majority of patients with prosthetic hip infection,
further major operations are required in an attempt to
clear infection and reduce the need for joint excision or
amputation. Surgical revision involves prosthesis removal
and debridement with either immediate (one-stage) or
delayed (two-stage) joint replacement or with excision
(Girdlestone procedure). In England and Wales, about 500
hip revision procedures per year are required as a conse-
quence of infection with treatment in one-stage revision
(30%), two-stage revision (64%) or excision (6%) [1]. Two-
stage revision is traditionally regarded as being more effec-
tive in treating infection, which probably explains the pre-
ponderance of two-stage revisions. The requirement of an
extra hospital admission and a further major surgical pro-
cedure, however, means that a two-stage revision may cost
70% more than a one-stage revision [14].
Patients who undergo a two-stage revision are left
without a joint between stages, and this is associated
with pain and considerable disability. The period
between stages is typically 2 to 12 months. In some
patients, health status and infection severity may indi-
cate that one revision method is appropriate [4]. In
many cases where there is no clear advantage of one
surgical method over another, however, the decision
about treatment is made at the discretion of the sur-
geon. Using systematic review methods, we explored the
evidence base supporting these decisions. We aimed to
review evidence on the effectiveness of one-stage and
two-stage revision in preventing reinfection after pros-
thetic hip infection.
Methods
We used systematic review methods based on those
described in the Cochrane Handbook for Systematic
Reviews of Interventions [15] and in accordance with the
Meta-analysis of Observational Studies in Epidemiology
(MOOSE) proposal for reporting systematic reviews and
meta-analysis of observational studies [16]. A MOOSE
checklist is shown in Additional file 1, Table A1.
We searched the Embase, MEDLINE and Cochrane
databases up to March 2011 for reviews, longitudinal
studies and clinical trials. The search strategy used in
MEDLINE is shown in Additional file 1, Table A2. The
search included terms relating to hip replacement, infec-
tion and revision and focused on one- and two-stage
surgeries. Thus, the search should have identified all
studies in patients receiving contemporary surgical treat-
ment options. We also searched reference lists and per-
formed a citation search of key articles in the ISI Web
of Science portal. No language restrictions were applied,
which is an important consideration with the perceived
international interest in treatment of infected hip
prostheses.
Results of searches were stored in an EndNote X3/4
database (Thomson Reuters, New York, NY, USA). One
reviewer (ADB) scanned titles and abstracts. Potentially
relevant articles were acquired, and inclusion decisions
were made separately, by two reviewers (ADB and
KTE). Ultimately, decisions on inclusion were based on
consensus.
We aimed to classify studies as follows: systematic
reviews, randomised controlled trials or longitudinal stu-
dies in all patients with infection treated exclusively by
one- or two-stage methods or by a variety of methods
(including some by one- and some by two-stage). Stu-
dies excluded from this analysis reported case series of
methods in selected patients (subsamples of patients
who received revision in one or two stages or patients
with a specific infection), had no outcomes by intention
to treat, reported data for hip and knee combined or did
not include patients with less than 2 years of follow-up.
To assess whether this selection strategy affected out-
comes, we also analysed 2-year outcomes in any groups
of patients who had received either one- or two-stage
revision. We did not include studies where patients
were treated only by joint excision with no prosthesis
replacement.
Data were extracted in duplicate by two reviewers
(ADB and KTE), with discrepancies resolved by discus-
sion. Good practice in systematic reviews includes con-
tact with authors to obtain additional information [15].
We did not contact authors, however, as many studies
were published over 20 years ago and therefore we did
not anticipate a good response.
The outcome we considered was reinfection within 2
years. No attempt was made to distinguish reinfection
with the same or a new pathogen. As small case series
are prone to selection issues, we report all studies in
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nal studies (50 or more patients) in detail. To compare
outcomes between methods, we created pooled random-
effects estimates using the Freeman-Tukey arc-sine
transformation to stabilise the variances.
Results
The progress of the review is shown in Additional file 1,
Figure A1. In our searches of databases, reference lists
and citations, we identified 523 articles, 168 of which
were subsequently found to be potentially relevant to
this review. After reading the full papers, we included
66 articles in the review. The papers that we excluded
mainly were selected case series of a particular surgical
method rather than longitudinal studies of infected hip
prostheses. The reasons for exclusion and references to
the excluded studies are detailed in Additional file 1,
Figure A1, and the references given in the Additional
material.
The following studies were included: two systematic
reviews comparing one- and two-stage methods in long-
itudinal studies [17,18], eleven studies (thirteen articles)
of exclusively one-stage revisions (articles A1 to A13),
twenty-eight studies (twenty-seven articles) of exclu-
sively two-stage revisions (articles A14 to A40) and
twenty-three studies (twenty-four articles) where treat-
ments comprised one- or two-stage revisions and/or
other surgical methods (articles A41 to A64). Two stu-
dies were randomised controlled trials evaluating use of
antibiotic beads (article A30) or spacer (article A14),
and groups were treated as separate studies. However,
no randomised trials comparing one- and two-stage
methods were identified.
The review article reported by Gallo and colleagues
compared the outcomes of one-stage and two-stage revi-
sions and excision arthroplasty in longitudinal studies
[17]. The authors used systematic search methods but
did not show the details of the 77 included studies pub-
lished up to November 2006 in patients with hip and
knee infections. The use of relative risks in their study
indicates that the authors included studies where one-
and two-stage methods were conducted in the same
population. This approach does not address expected
bias arising from selection of patients by health status
and infection severity.
In their review, Wolf and colleagues reported an
increased reinfection rate after one-stage revisions
(12.3%) compared with two-stage revisions (6.5%) of
infected total hip replacement [18]. In the studies they
classified as two-stage revisions, however, more patients
died. Searches up to May 2008 were limited to MED-
LINE and publications in a major orthopaedic journal.
Longitudinal studies that we identified, regardless of
size, are summarised in Additional file 1, Table A3. This
includes descriptive information, our justifications for
including the study as unselected (consecutive prosthetic
hip infections) and the outcome as reflecting infection
within 2 years of revision (if described). We also present
an estimate of the 2-year reinfection rate in each study.
Studies including 50 or more patients are summarised
in Table 1.
The studies we included reported data from infected
hips identified over extended periods with a mean of 8.5
years (range 3 to 17 years) for studies of exclusively
one- or two-stage revisions. Generally, information on
reinfection was clear, and, in some articles, data on indi-
vidual patients was provided. Where possible, we used
data on reinfection within 2 years of treatment, but this
was not always the case.
One-stage revisions
Reinfection rates in the five studies with over 50
patients (range 72 to 640) were 15.5% [19], 8.9% [20],
7.9% [21], 3.3% [22] and 26.4% [23]. In three of the stu-
dies, the use of antibiotic-loaded bone cement was stu-
died [19,20,22].
An early series described by Buchholz and colleagues
included 640 revisions of infected hip prostheses treated
exclusively by a one-stage procedure [19]. The authors
reported “bad results,” which included failure to eradi-
cate infection and achievement of stable joint replace-
ment. The authors reported a success rate of 77% after
one-stage revision, with a stable, infection-free joint
achieved in 90% of patients after further revision opera-
tions. By estimating an outcome related directly to
infection, we calculated that 15.5% of patients had early
reinfection. This may represent an overestimate, how-
ever, because we cannot be certain that all of these rein-
fections occurred within 2 years or that all second
exchange operations were performed as a consequence
of reinfection.
In 90 patients followed up by Loty and colleagues, the
rate of reinfection within 2 years was 8.9% [20]. This
may have been an underestimate, however, as seven
patients (7.8%) were lost to 2-year follow-up. Long-term
function measured by the Merle d’Aubigné-Postel score
was good or very good in 79% of patients followed up.
Miley and colleagues reported a study of 100 patients
with 101 infections after hip surgery and reported out-
comes from grades I to IV [21]. Grade IV, reflecting
drainage, constant pain and the suggestion of a need for
further surgery, was recorded in 7.9% of hips. The inci-
dence of reinfection within 2 years was not specified.
Raut and colleagues reported on a cohort of 183
patients, among whom the reinfection was 3.3% within
2 years of revision of infected hip replacement [22,24].
N op a i n ,a sm e a s u r e db yt h eM e r l ed ’Aubigné-Postel
score, was reported by 69% of patients at last follow-up.
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Study
Country
Year of
study
Patient treatments
Number of participants
Mean age (% men)
Exclusive surgical method
Treatment
Overall follow-up
Outcomes
Deaths and losses to follow-up
N (%) reinfection at 2
years
Details
One-stage
Buchholz et
al., 1981 [19]
Germany
1968 to 1977
Hip arthroplasty for OA
(95%), others (5%)
N = 640
58.8 years (39.7%)
“Patients with deep infection
involving arthroplasties of the hip” (p.
344).
Antibiotic-loaded cement
52 months
Need for further exchange,
reinfection
90 deaths
99 (15.5%)
Reoperation due to “bad”
outcome plus other
infection-related outcomes
Loty et al.,
1992 [20]
France
1980 to 1988
THR
N =9 0
65.7 years (not specified)
“We usually manage infected total hip
replacements by a one stage revision”
(p. 330).
Systemic antibiotics and antibiotic-
loaded cement
47 months ± 29 months
Reinfection, other failure, Merle
d’Aubigné-Postel score
Four deaths, seven lost to follow-
up
8 (8.9%)
Infections occurred
between 6 and 24 months
Miley et al.,
1982 [21]
USA
1969 to 1979
Hip surgery for fracture
dislocation (47%), OA
(36%), others (17%)
N = 100 (101 hips)
Men 56.2 years, women 59
years (53%)
“The operating surgeon must be
prepared to perform either of these
operations (1-stage or Girdlestone),
depending on the surgical findings
and medical work-up” (p79).
Intensive multiple-drug antimicrobial
programme
48.5 months, minimum 32
months
Grading system focusing on
quality of life and hip function.
Grade IV outcome: drainage,
constant pain, further surgery
suggested
11 deaths
Eight hips (7.9%) Grade IV
outcome
No information on
reinfection within 2 years
Raut et al.,
1995 [22]
Wroblewski,
1986 [24]
UK
1979 to 1990
Cemented primary THR
(63%), revision THR (37%)
N = 183
64.5 years (48%)
“All infected arthroplasties during this
period were treated with 1-stage
reimplantation, irrespective of the
organism that was cultured, unless
the patient had poor quality bone
stock.” (p. 202. Wroblewski, 1986 [24])
Antibiotic-loaded cement
93 months, range 24 to 164
months
Persistent infection, Merle
d’Aubigné-Postel score (pain,
function and movement),
radiology, re-revision,
complications.
14 deaths (0 in year 1)
6 (3.3%)
Reinfection in first 2 years
Schneider,
1989 [23]
Switzerland
1973 to 1988
Hip implants
N = 72 (excluding 13
treated with irrigation
alone)
Not specified
“Between 1980 and 1988, out of 42
deep infections....” (p. 527)
Data also included from 1973
onwards
Joint irrigation preceding revision
Follow-up interval not specified.
Reinfection (bad outcome)
19 (26.4%), rate from 1980
(16.1%)
No information on
reinfection within 2 years
Two-stage
Chen et al.,
2009 [25]
Taiwan
1993 to 2005
THR (excluding patients
with proximal femoral
allograft reconstruction)
N =5 7
51.5 years (72%)
“[A]ccording to the protocol for short-
term parenteral antibiotics therapy at
this institution....” (p. 189).
Interim antibiotic-impregnated
cement beads
67.2 months
Reinfection, Harris hip scores,
radiological examinations
Five deaths and five lost to
follow-up
7 (12.3%)
Reinfection in seven
patients after first stage
described in text
Fitzgerald
and Jones,
1985 [26]
USA
1969 to 1979
Hip implant
N = 131
61 years (50%)
“[D]elayed reconstruction in 131
patients who had an infection after a
previous total hip arthroplasty....”
(p.828. McDonald et al. 1989 [32]).
Intensive
Cemented reconstruction with no
added antibiotic
49 months; range 2 to 9 years
Reinfection
All hip implants
11 (8.4%)
Reinfection up to 429 days
McDonald et
al., 1989 [32]
1969 to 1985
Specifically THR for OA
(69%), fracture (13%), other
(18%)
N = 81 (including
additional 13 patients)
60.0 years (53%)
5.5 years, range 2.0 to 13.6 years
Reinfection, complications
THR only
6 (7.4%) estimated from
survival curve
Haddad et
al., 2000 [27]
UK
1988 to 1992
THR for OA (72%), other
(28%)
N =5 0
60 years (46%)
“[C]onsecutive patients all of whom
were referred with an infected total
hip replacement and treated using a
standardised protocol” (p. 689).
Antibiotic-loaded beads and cement
ball
Uncemented
5.8 years, range 2 to 8.7 years
Reinfection, Harris hip score,
radiological outcome,
complications
Two deaths
4 (8%)
No information on
reinfection within 2 years
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Hsieh et al.,
2009 [28]
Taiwan
2002 to 2005
Prosthetic hip
N =9 9
61 years (61%)
“The use of an ALCS in SEA for PHI
has been a routine practice in our
institution” (p. 93).
Antibiotic-loaded cement spacer
43 months, range 24 to 60
months
Reinfection, Merle d’Aubigné-
Postel score (only in comparisons
of antibiotic strategies),
radiographic results
Three deaths, five lost to follow-
up
8 (8.1%)
Reinfection between stages
Romanò et
al., 2010 [29]
Italy
2000 to 2007
Hip prostheses
N = 102
58 years (34%)
“102 consecutive patients underwent
two-stage revision of septic hip
replacement” (p. 26).
Long-stem or short-stem preformed
antibiotic-loaded cement spacers
Cementless
48 months
Reinfection, Harris hip score (only
in comparisons of antibiotic
strategies)
Three deaths, nine lost to follow-
up
5 (4.9%)
Reinfection within 3 years
(including between stages)
Stockley et
al., 2008 [30]
UK
1991 to 2004
THR for OA (60%),
posttraumatic arthritis
(18%), others (23%)
N = 114
64 years (55%)
“[C]onsecutive patients with
microbiologically-proven deep chronic
infection of the hip were managed by
a two-stage exchange procedure”
(p.145).
Antibiotic-loaded cement beads
74 months, range 2 to 175
months
Reinfection
9 (7.9%)
Reinfection within 1 year
Toulson et
al., 2009 [31]
USA
1989 to 2003
THR
N = 132
54.7 years (59%) in patients
“who completed the entire
protocol” (p.1054)
“All 132 cases of infected THAs
treated at our institution....” (p.1052).
Spacer containing antibiotic
impregnated cement used in 67%
64.8 months, range 24 to 203
months; eight patients followed
for only an average of 7.2
months
Reinfection, Harris hip score
(mean only)
34 deaths (2 with no infection
information), 8 lost to follow-up
11 (8.3%)
Three new infections within
24 months, four infections
not eradicated, four patients
who died had infections
Combination
of methods
De Man et
al., 2011 [33]
Switzerland
1985 to 2004
THR
N = 79 hips
70 years (57%) in patients
followed up
One-stage (n = 24), two-stage (n =
55)
Some patients had spacers between
stages
Mean 3.8 years (SD 2.2)
Reinfection, Harris hip score
including limping and walking,
radiographic outcome
Seven lost to follow-up
Overall (n = 2, 2.5%)
One-stage (n = 1, 4.5%)
Two-stage (n = 1, 2.0%)
Elson, 1993
[34]
UK
Not specified
THR
N = 296 (definite or
possible infection)
Not specified
One-stage (n = 235), two-stage (n =
61)
Antibiotic-loaded cement pellets used
in two-stage method
Not specified
Reinfection, mechanical survival,
radiological outcome
Overall (n = 36, 12.2%)
One-stage (n = 33, 14.0%)
Two-stage (n = 3, 4.9%)
Time of definite or possible
reinfection (mean 25
months, range 1 to 68
months)
Ketterl et al.,
1988 [35]
Germany
1976 to 1986
THR
N = 207
69 years (42%)
One-stage (n = 21), two-stage (n =
161), no reimplantation (n = 25)
Gentamicin cement
32 months
Reinfection, function
Overall (n = 24, 11.6%)
One-stage (n = 7, 33.3%)
Two-stage (n = 17, 10.6%)
Time of reinfection unclear
Ladero
Morales et al.,
1999 [36]
Spain
1985 to 1995
THR
N = 62 (another 12 with
nonsurgical treatment)
74 years (53%)
One-stage (n = 2), two-stage (n = 37),
resection-only (n = 23)
Some treated after introduction of
perioperative antibiotic protocol
4.8 years
Reinfection, Merle d’Aubigné-
Postel score, clinical and
functional outcome (pain,
mobility, gait)
Overall (n = 3, 4.8%)
One-stage (n = 0, 0%)
Two-stage (n = 3, 8.1%)
Time of reinfection unclear
Lecuire et al.,
1999 [37]
France
1982 to 1997
THR
N =5 7
70.6 years
One-stage (n = 16), two-stage (n =
41)
Uncemented
6.6 years
Reinfection, Merle d’Aubigné-
Postel scale, Harris hip score
Overall (n = 2, 3.5%)
One-stage (n = 1, 6.3%)
Two-stage (n = 1, 2.4%)
Time of reinfection unclear
Oussedik et
al., 2010 [38]
UK
1999 to 2002
THR
N =5 0
65 years (42%)
One-stage (n = 11), two-stage (n =
39)
Antibiotic-loaded spacer used in two-
stage
Gentamicin-loaded cement used in
one-stage
6.8 years, range 5.5 to 8.8 years
Reinfection, Harris hip score, VAS
satisfaction
Overall (n = 2, 4.0%)
One-stage (n = 0, 0%)
Two-stage (n = 2, 5.1%)
No information on
reinfection within 2 years
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outcomes.
Schneider followed up 72 patients with infected hip
implants [23]. A bad outcome, mainly reinfection, was
reported in 26.4% of patients, but this may have
included those with reinfection after 2 years. The author
reported that the reinfection rate in patients with infec-
tion identified from 1980 onwards was 16.1%.
Two-stage revisions
Seven studies of 50 or more patients reported outcomes
of two-stage revisions of infected hip prostheses. The
reinfection rates reported were 12.3% [25], 8.4% [26],
8.0% [27], 8.1% [28], 4.9% [29], 7.9% [30] and 8.3% [31].
Antibiotic-loaded cement beads [25,27,30] or spacers
[28,29,31] were used between stages in six studies.
Chen and colleagues reported a 2-year reinfection rate
of 12.3% after treatment of infected hip replacement
[25]. This was mainly restricted to the period between
stages, with repeated debridements used to achieve a
lower proportion of patients with infection at 2 years
(3.5%). An excellent or good functional recovery accord-
ing to the Harris hip score was recorded in 74% of
patients. In a study of 131 patients with infected hip
implants, Fitzgerald and Jones reported a reinfection
rate within 14 months of 8.4% [26,32]. Haddad and col-
leagues followed up 50 patients with infected hip repla-
cement and reported reinfection in 8.0% of them [27]. It
was not clear whether these reinfections occurred within
2 years of hip replacement. A good or excellent func-
tional outcome according to the Harris hip score was
achieved by 78% of patients.
In a study of 99 patients with infected hip prostheses,
Hsieh and colleagues reported reinfection between
stages in 8.1% of patients [28]. Romanò and colleagues
followed up 102 patients with infected hip prostheses
[29]. Within 3 years of revision, 4.9% of patients had
reinfection. A further 8.8% of patients were lost to fol-
low-up. In a study of 114 patients with infected total hip
replacement, Stockley and colleagues reported reinfec-
tion within 1 year in 7.9% of patients [30]. Toulson and
colleagues reported reinfection in 8.3% of patients
within 2 years of total hip replacement [31].
Studies with combination of one-stage, two-stage and
excision procedures
In addition to the studies of specifically one-stage and
two-stage revisions, searches identified studies in which
patients with infected hip prostheses were followed up
after treatment by any one of one-stage, two-stage or
excision methods. In eight studies of 50 or more
patients, the rates of reinfection were 2.5% [33], 12.2%
[34], 11.6% [35], 4.87% [36], 3.5% [37], 4.0% [38], 20.0%
[39] and 15.7% [40]. Four of these studies had sufficient
one-stage and two-stage revisions to compare reinfec-
tion outcomes.
Elson reported almost three times the rate of reinfec-
tion over a range of 1 to 68 months after one-stage as
two-stage revisions [34]. He did not present information
on patient characteristics, however, and acknowledged
that the difference in infection rates represented “an
oversimplification of the many complex factors involved
in the analysis of these results” [41] (p. 761).
Ketterl and colleagues reported a threefold increase in
the risk of reinfection in patients treated with one-stage
revision compared with two-stage revision [35]. Again,
no information was provided regarding the characteris-
tics of patients who underwent procedures using the dif-
ferent revision methods. Also, no information was
provided on patients who did not receive implantation
in a planned two-stage procedure. If these were classi-
fied as failed two-stage revisions, the reinfection rate
would increase from 10.6% to 26.1%.
In the large, multicentre study comprising 458
patients with surgical revision reported by Vielpeau and
Lortat-Jacob, the rate of reinfection in patients who
underwent one-stage revision was 11.8% compared with
14.9% in those who underwent two-stage revision [40].
Table 1 Characteristics of included studies with 50 or more patients (Continued)
Sanzén et al.,
1988 [39]
Carlsson et
al., 1978 [42]
Sweden
1974 to 1981
THR for OA (74%),
congenital dislocation (8%),
fracture (8%), others (10%)
N = 108 (110 hips)
64 years (53%)
One-stage (n = 78 hips), 2-stage (n =
32 hips)
In 44% of two-stage procedures,
gentamicin-loaded PMMA beads were
used
Gentamicin-loaded cement
71 months, range 24 to 117
months
Reinfection, loosening, function
Eight deaths within 24 months
Overall (n = 22, 20.0%)
One-stage (n = 17, 21.8%)
Two-stage (n = 8, 25.0%)
At least 22 of 25
reinfections in first year
Vielpeau and
Lortat-Jacob,
2002 [40]
France
Up to
December
1998
THR
N = 458 (including
acetabular or femoral
revision only, excluding
methods with retention of
components)
No age or sex details
One-stage (n = 127), two-stage (n =
222), resection (n = 81)
Antibiotic cement (n = 249), no
antibiotic cement (n = 100) in one or
two stages
Median 3 years, 81.5% followed
for minimum of 2 years
Reinfection, complications
Overall (n = 72, 15.7%)
One-stage (n = 15, 11.8%)
Two-stage (n = 33, 14.9%)
ALCS, antibiotic-loaded cement spacer; OA, osteoarthritis; PHI, prosthetic hip infection; PMMA, polymethylmethacrylate; SEA, staged exchange arthroplasty; THA,
total hip arthroplasty; THR, total hip replacement; VAS, Visual Analogue Scale.
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tion within 2 years specifically, and about 18% of
patients died or were lost to follow-up.
Sanzen and colleagues reported a 13% reduction in
reinfection in patients who received a one-stage com-
pared with a two-stage replacement [39]. Unlike the
reporters of the previous studies, these authors
described the process by which patients were allocated
to one- or two-stage revision; in the earlier years of
their study, treatment at one hospital was by one-stage
revisions and in two hospitals by two-stage procedures
[42].
Comparison of methods
To compare methods, we included all studies with rein-
fection outcomes, regardless of the number of patients
studied. Point estimates and confidence intervals for the
proportions of patients with reinfection are shown in
Figure 1.
In the 11 studies of exclusively one-stage revision
comprising 1,225 patients, the pooled-effect estimate of
incidence of reinfection using a random-effects model
was 8.6% (95% CI = 4.5 to 13.9). Substantial heterogene-
ity was evident among the studies (c
2 = 59.06, df =1 0 ,
P =0 . 0 0 0 ,I
2 = 83.1%). In a fixed-effects analysis, the
pooled incidence rate was 11.4% (95% CI = 9.7 to 13.3).
The discrepancy with the random-effects model was
mainly explained by the large study of Buchholz and
colleagues. Excluding this study, with its less specific
outcome measure of the need for second exchange and
other reinfections, the pooled random-effects estimate
was 7.7% (95% CI = 3.6 to 13.4) and heterogeneity was
reduced slightly (c
2 = 39.61, df =9 ,P = 0.000, I
2 =
77.3%).
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75
Two year re-infection rate (%)
ONE-STAGEn /N
Buchholz (1981) 99/640
Raut (1995) 6/183
Miley (1982) 8/101
Loty (1992) 8/90
Schneider (1989) 19/72
Winkler (2006) 3/37
Rudelli (2008) 0/32
Ure (1998) 0/20
Wagner (1995) 4/18
Sofer (2005) 1/17
Mulcahy (1996) 0/15
TWO-STAGE
Toulson (2009) 11/132
Fitzgerald (1985) 11/131
Stockley (2008) 9/114
Romano (2010) 5/102
Hsieh (2009) 8/99
Chen (2009) 7/57
Haddad (2000) 4/50
Lieberman (1994) 8/47
Whittaker (2009) 6/43
Colyer (1994) 5/41
Fink (2009) 0/40
Cabrita (2007a) 4/38
Cordero-Ampuero (2009) 3/36
McKenna (2009) 0/31
Cabrita (2007b) 10/30
Piriou (2003) 3/30
Fehring (1999) 1/25
Evans (2004) 4/23
Wilson (1989) 2/22
Yamamoto (2003) 0/17
Cordero-Ampuero (2007) 1/16
Nelson (1993a) 2/12
Magnan (2001) 2/10
Nelson (1993b) 4/10
Dairaku (2009) 1/9
Takahira (2003) 1/8
Takigami (2010) 0/8
Sudo (2008) 1/7
Summary*
One-stage
Two-stage
One or two stage
Figure 1 Proportions of patients with reinfection within 2 years after treatment in studies of one- and two-stage revision in
unselected patients. N represents the total number of patients treated surgically, n represents the number of patients with reinfection. Cabrita
a and b and Nelson a and b refer to randomised intervention and control groups, respectively. *Summary values for one-stage, two-stage and all
studies (including studies with unselected patients with one- and two-stage revision; data not shown) were calculated using a random-effects
model and the Freeman-Tukey arc-sine transformation to stabilise the variances.
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Page 7 of 10In the 28 studies comprising 1,188 patients treated
exclusively with two-stage revision, the pooled random-
effects estimate for the incidence of reinfection was
10.2% (95% CI = 7.7 to 12.9). The heterogeneity among
studies was moderate (c
2 =5 1 . 7 3 ,df =2 7 ,P = 0.003, I
2
= 47.8%).
Overall, across the 62 studies comprising 4,197 unse-
lected patients (or hips) treated for prosthesis infection,
the reinfection incidence using a random-effects model
was 10.1% (95% CI = 8.2 to 12.0) with substantial het-
erogeneity (c
2 = 209.42, df = 61, P = 0.000, I
2 = 70.9%).
We also took the opportunity to compare reinfection
rates for all the studies we identified that reported rein-
fection rates after one- and two-stage revision proce-
dures. This included patients selected by a surgeon for a
particular method on the basis of health status and
infectious agent. The results of 133 studies comprising
5,556 patients are summarised in Additional file 1, Fig-
ure A2. In a random-effects analysis, the rates of rein-
fection after one- and two-stage revisions were 10.56%
(95% CI = 8.12 to 13.31) and 8.71% (95% CI = 7.32 to
10.17), respectively. Overall, across all studies of surgical
revision using one- and two-stage methods, the rate of
reinfection was 9.19% (95% CI = 7.96 to 10.50). Hetero-
geneity was moderate (c
2 = 289.67, df =1 3 2 ,P = 0.000,
I
2 = 54.4%).
Discussion
About 10% of surgical revision procedures for infected
hip prostheses become reinfected within 2 years. Pooled
estimates of reinfection outcomes with wide confidence
intervals do not suggest that outcomes are worse after
one-stage compared with two-stage revision.
Evidence on the relative effectiveness of one- and two-
stage revisions in preventing reinfection of hip pros-
theses is largely based on interpretation of longitudinal
studies. Reviews of longitudinal studies and particularly
case series are limited by the possibility of publication
bias and other sources of bias. We used systematic
review methods to identify studies that described out-
comes specifically after one-o rt w o - s t a g er e v i s i o n si n
consecutive and generally unselected patients.
Despite our aim to include only studies of unselected
patients undergoing surgical revision, we recognise an
earlier phase of selection related to management without
further replacement. Different protocols, eligibility cri-
teria and use of treatments with prosthesis retention
may affect the representativeness of the study popula-
tions we included and may explain the high degree of
statistical heterogeneity we observed. As is true of a
review of treatment of infected knee prostheses by Jäm-
sen and colleagues, however, we believe that it is impor-
tant to attempt to include “only papers reporting a pure
series of either one-stage or two-stage revision” [43] (p.
72). This is supported by the somewhat different rein-
fection rates we observed when we included studies that
included patients selected for a particular revision
method on the basis of infection severity and other
aspects of patient health.
In this overview of studies in unselected patients, we
specified prevention of reinfection as the key aim of
revision surgery. In discussions with our advisory group
of patients with joint replacement, patients recognised
that clearance of infection is of paramount importance.
Achievement of a functional, painless hip is the aim of
any revision hip replacement [44], however, and the
importance of patient-reported outcomes in assessing
joint replacement outcome is widely recognised [45]. In
their review, Wolf and colleagues explored patient pre-
ferences for one- or two-stage revision in a Markov
simulation model [18]. In addition to outcomes reported
in longitudinal studies, they used data collected from
nonorthopaedic outpatients on trade-offs between
impaired health versus full health with shortened life, as
well as time with constant severe pain. They concluded
that, compared to a two-stage procedure, one-stage revi-
sion was associated with greater benefit in terms of
quality-adjusted life years.
One- and two-stage methods are perceived to have
specific advantages and disadvantages. With a one-stage
approach and a single major surgery, recovery is
quicker. The advantages of two-stage treatment relate to
the opportunity to apply an enhanced antimicrobial
strategy between excision and reimplantation surgeries.
The results of bacteriological samples obtained at sur-
gery can be used to guide antibiotic treatment, and the
period between stages is an opportunity for insertion of
antibiotic-impregnated cement beads into the joint
space. In two-stage revisions, however, patients experi-
ence considerable restriction of movement during the
period between implant removal and replacement [4].
Two-stage revision is often considered essential for
more virulent infections. Nevertheless, Leung and col-
leagues reported a reinfection rate of 21% after two-
stage revision in patients with resistant infections [46].
To reduce long-term problems resulting from an
extended period without an implant, an antibiotic-
impregnated cement “spacer” may be used to maintain
some function and a correct leg length and to reduce
long-term problems associated with disuse. Although
spacers improve patient mobility, complications can
arise. For example, in 88 spacer implantations per-
formed by Jung and colleagues, there were 15 spacer
dislocations (17%), 9 spacer fractures (10%) and an over-
all complication rate of 58.5% [47].
The economic implications of uncomplicated one- and
two-stage revision differ considerably. Although a one-
stage procedure may require a prolonged hospital stay
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Page 8 of 10to facilitate intravenous antibiotic therapy, the main
determinant of cost is the requirement for additional
surgery in a two-stage revision. In the United Kingdom,
the cost to the NHS of each complicated hip procedure
is over £8,000 [48]. Klouche and colleagues estimated
that the cost of managing a patient with an infected hip
prosthesis is 3.6 times greater than that of a primary
total hip replacement and that two-stage revisions cost
1.7 times more than one-stage revisions [14].
Forty-three years of data collection do not conclusively
support a specific treatment for prosthetic hip infection.
The thoroughness of data collected over extended peri-
ods suggests the possibility of individual patient data
synthesis with time-to-event analyses [49]. We concur
with Matthews and colleagues, however, that large, mul-
ticentre, randomised trials are needed to establish opti-
mum management strategies [4], and this is particularly
apparent regarding surgical options. It could be argued
that appropriate randomised trials are not feasible
because of the limited opportunities of an individual
surgeon to gain experience in using a particular techni-
que. However, the surgical techniques familiar to sur-
geons operating with the more widely used two-stage
strategy and with aseptic revision (a single-stage revi-
sion) include most of the skills required.
The acceptability to patients of methods and their eva-
luation is of overriding importance. It is notable that
only two studies collected data regarding patient-centred
outcomes. If reinfection rates are similar between meth-
ods, the possibility of a single major surgery, reduced
overall hospitalisation and avoidance of a prolonged per-
iod without a permanent implant would make a one-
stage procedure preferable. Conversely, it could be
argued that the long-term, targeted antibiotic regimen
associated with contemporary two-stage treatment
should not be withheld.
Prosthetic hip infection is sufficiently rare to make a
single, definitive randomised trial unlikely. Conducting
multiple smaller trials in which patients’ experiences
and patient-reported outcomes are recorded, together
with a systematic overview of infection outcome, may be
a more valid approach, and this would also allow
exploration of methodological variability and other
sources of heterogeneity [50]. Research into the patient
experience of prosthetic hip infection and its treatment
is urgently required. This will help in the development
of studies that identify the best method for treatment of
prosthetic joint infection.
Conclusions
Evidence of the relative effectiveness of one- and two-
stage surgical revision in treatment of infected hip pros-
theses is largely based on interpretation of longitudinal
studies. There is no suggestion on the basis of systema-
tic review of published studies that one- or two-stage
methods have different reinfection outcomes. Rando-
mised trials are needed to establish optimum manage-
ment strategies.
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